Drug
CPX-351 clinical trials
Also written CPX-351.
- studies test it
- 62
- open now
- 16
- in phase 3
- 6
- first study started
- 2006
Keep track of what changes. Save the CPX-351 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
61 studies that test it; most in 2019 (12); 1 more planned to start later
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 6 |
| 2019 | 12 |
| 2020 | 9 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 25
- Phase 2
- 42
- Phase 3
- 6
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 53
Jazz Pharmaceuticals (8) · M.D. Anderson Cancer Center (7) · Fred Hutchinson Cancer Center (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Weill Medical College of Cornell University (3) · Children's Oncology Group (3) · National Cancer Institute (NCI) (3) · Case Comprehensive Cancer Center (2)
Often tested with
Tested in the same studies.
Cytarabine (8) · Venetoclax (8) · Azacitidine (5) · Fludarabine (4) · Gemtuzumab (4) · Quizartinib (3) · Gilteritinib (3) · Glasdegib (2)
Studies
Open first, then newest update. How each study uses CPX-351 is read from its arms, and is right about nine times in ten.
Testing it · 62
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Liposome-encapsulated Daunorubicin-Cytarabine
- Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)RecruitingPhase 1/2Masonic Cancer Center, University of MinnesotaNCT07008638Written as CPX-351
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05554406Written as Liposome-encapsulated Daunorubicin-Cytarabine
- CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaRecruitingPhase 1M.D. Anderson Cancer CenterNCT03896269Written as Liposome-encapsulated Daunorubicin-Cytarabine
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)Not yet recruitingPhase 2National Cancer Institute (NCI)NCT05554419Written as Liposome-encapsulated Daunorubicin-Cytarabine
- Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT03629171Written as Liposome-encapsulated Daunorubicin-Cytarabine
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsRecruitingPhase 3Children's Oncology GroupNCT04293562Written as Liposome-encapsulated Daunorubicin-Cytarabine
- Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After InductionRecruitingPhase 1/2Ohio State University Comprehensive Cancer CenterNCT04049539Written as Liposome-encapsulated Daunorubicin-Cytarabine
- CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 2M.D. Anderson Cancer CenterNCT04493164Written as Liposome-encapsulated Daunorubicin-Cytarabine
- Phase IB/II of CPX-351 for Relapse Prevention in AMLRecruitingPhase 1/2Georgetown UniversityNCT04990102Written as CPX-351
- CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AMLRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05558124Written as Vyxeos
- Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute LeukemiaRecruitingPhase 1Children's Hospital Medical Center, CincinnatiNCT03826992Written as Vyxeos
- Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AMLRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05024552Written as Vyxeos
- Vyxeos® With Clofarabine for Pediatric AMLRecruitingPhase 1Princess Maxima Center for Pediatric OncologyNCT07156435Written as Vyxeos 44 MG / 100 MG Liposome Injection
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial TreatmentNot yet recruitingPhase 2Eastern Cooperative Oncology GroupNCT05628623Written as CPX-351
- A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid LeukemiaNot yet recruitingPhase 3CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT06182592Written as Liposomal cytarabine-daunorubicin for injection
- Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid NeoplasmsActive, not recruitingPhase 2St. Jude Children's Research HospitalNCT05656248Written as CPX-351
- Vyxeos for Induction of Low- or Intermediate-risk.Active, not recruitingPhase 2Shaare Zedek Medical CenterNCT05599360Written as Vyxeos
- Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AMLCompletedPhase 2GWT-TUD GmbHNCT04061239Written as CPX-351
- CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years OldCompletedPhase 2Roswell Park Cancer InstituteNCT04269213Written as Liposome-encapsulated Daunorubicin-Cytarabine
See all 62 studies that test CPX-351 →
Given in every arm · 7 — CPX-351 is usual care beside what is tested
- Tazemetostat and Palbociclib With CPX-351for R/R AMLRecruitingPhase 1Thomas Jefferson UniversityNCT05627232Written as Liposome-encapsulated Daunorubicin-Cytarabine
- A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for InjectionRecruitingNot applicableCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT05801835Written as Vyxeos
- Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04802161Written as Liposome-encapsulated Daunorubicin-Cytarabine
- Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDSWithdrawnPhase 2Uwe PlatzbeckerNCT05829434Written as CPX-351
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid LeukemiaCompletedPhase 1Jazz PharmaceuticalsNCT04075747Written as CPX-351
- CPX-351+GO in Subjects 55 Years Old, or Older, With AMLTerminatedPhase 1Weill Medical College of Cornell UniversityNCT03878927Written as CPX-351
- Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.TerminatedPhase 2University of California, San DiegoNCT04425655Written as Vyxeos
As the comparator · 1 — what is tested is compared with CPX-351
Codes
What other systems call CPX-351 · ClinicalTrials.gg INT001046
- MeSH (NLM) C000629812CPX-351One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629812 | CPX-351 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.